Table 3 Details on the performance evaluation of HUST-19 for the prediction of morbidity outcomes using data from cohort 2
Prediction | Type | AUC | Sn (%) | Sp (%) | Ac (%) | PPV (%) | NPV (%) | MCC |
|---|---|---|---|---|---|---|---|---|
CT based | Control | 0.895 | 53.57% | 94.47% | 83.70% | 77.59% | 85.06% | 0.5486 |
Type I | 0.775 | 86.67% | 50.36% | 70.85% | 69.33% | 74.47% | 0.4027 | |
Type II | 0.832 | 32.73% | 95.08% | 84.33% | 58.06% | 87.15% | 0.3546 | |
CF based | Control | 0.888 | 54.72% | 99.59% | 86.04% | 98.31% | 83.56% | 0.6668 |
Type I | 0.834 | 72.53% | 78.70% | 75.50% | 78.57% | 72.68% | 0.5124 | |
Type II | 0.845 | 71.63% | 78.82% | 77.49% | 42.45% | 92.65% | 0.4200 | |
HUST-19 | Control | 0.944 | 51.19% | 98.30% | 85.89% | 91.49% | 84.93% | 0.6150 |
Type I | 0.860 | 80.56% | 76.26% | 78.68% | 81.46% | 75.18% | 0.5673 | |
Type II | 0.884 | 80.00% | 78.41% | 78.68% | 43.56% | 94.95% | 0.4743 |
